TScan Therapeutics, Inc. Cash Flow Statement
TCRX|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
TScan Therapeutics, Inc. used $111M in operating cash flow and negative free cash flow of $115M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$127.5M | -$89.2M | -$66.2M | -$48.6M | -$26.1M |
| Depreciation & Amortization | $4.1M | $5.4M | $5.1M | $3.3M | $1.2M |
| Operating Cash Flow | -$110.8M | -$61.4M | -$66.5M | -$48.7M | -$3.0M |
| Capital Expenditures | $3.8M | $3.1M | $4.2M | $9.9M | $4.2M |
| Free Cash Flow | -$114.6M | -$64.5M | -$70.7M | -$58.6M | -$7.3M |
| FCF Margin | -4071.3% | -306.4% | -522.6% | -578.0% | -669.2% |